People to Actively Manage Their Type 2 Diabetes

Bristol-Myers SquibbThe American Association of Clinical Endocrinologists (AACE) and its educational arm - the American College of Endocrinology (ACE) - in partnership with Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), announced a new public health initiative for people with type 2 diabetes mellitus called The Type 2 Talk: Changing the Type 2 Diabetes Conversation™. The program aims to help people with type 2 diabetes actively manage their disease by fostering an open and ongoing dialogue with their healthcare team about their comprehensive clinical care.

"As a practicing endocrinologist, I've observed that people with type 2 diabetes and doctors struggle to have a meaningful dialogue about this condition, making it challenging to create an effective and comprehensive treatment program for each patient," said Jeffrey I. Mechanick, MD, FACP, FACE, FACN, Secretary of the American Association of Clinical Endocrinologists. "We are launching The Type 2 Talk to foster more effective patient-physician conversations around type 2 diabetes care, in an effort to help patients and physicians work together to reach treatment goals."

Almost Half of Adults with Type 2 Diabetes Remain Uncontrolled on Their Current Therapy
The Centers for Disease Control and Prevention (CDC) estimate that approximately one in every 11 adults in the United States has diagnosed diabetes. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Despite exercising, eating right and anti-diabetic treatment, nearly half of adults living with type 2 diabetes still do not have their blood sugar levels under control. Time is of the essence in managing type 2 diabetes, as uncontrolled blood sugar can increase the risk of diabetic complications over time such as blindness, kidney disease, nerve damage, heart disease, amputations, and stroke.

A1C Testing To Help Manage Type 2 Diabetes
One important part of managing type 2 diabetes is for patients to receive a glycosylated hemoglobin level (HbA1c) test, or an A1C test, twice a year at minimum, or more frequently when necessary. This is a simple blood test conducted in a physician's office, or a lab, that reflects the approximate three-month average of blood sugar control and is important to determine whether a patient’s current treatment plan is working. AACE recommends that people with type 2 diabetes work with their healthcare team, including their endocrinologists, to reach an A1C value of 6.5 or less.

About The Type 2 Talk™
The Type 2 Talk: Changing the Type 2 Diabetes Conversation™ is an educational program that seeks to improve the dialogue between people with type 2 diabetes and their healthcare team. The program is designed to provide patients and physicians with practical advice and resources to help advance results-focused conversations about type 2 diabetes. TheType2Talk.com brings a new perspective to the patient-physician dialogue by highlighting the unique viewpoints of each party, and fostering a deeper mutual understanding of each other's needs. The Type 2 Talk website provides current insights, polls, and eye-opening facts in an effort to help physicians and patients work together to reach treatment goals.

About the American Association of Clinical Endocrinologists (AACE)
AACE is a professional medical organization with more than 6,000 members in the United States and 91 other countries. AACE members are physicians who specialize in endocrinology, diabetes, and metabolism.

About the American College of Endocrinology (ACE)
The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is the leader in advancing the care and prevention of endocrine and metabolic disorders by: providing professional education and reliable public health information; recognizing excellence in education, research and service; promoting clinical research and defining the future of clinical endocrinology.

Bristol-Myers Squibb and AstraZeneca Collaboration
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...